|
"yen cj"的相關文件
顯示項目 1-25 / 99 (共4頁)
1 2 3 4 > >>
每頁顯示[10|25|50]項目
| 國家衛生研究院 |
2024-06-21 |
A phase 1 study of biweekly nab-paclitaxel/oxaliplatin/S-1/LV for advanced upper gastrointestinal cancers: TCOG T1216 study
|
Tsai, HJ;Yang, SH;Hsiao, CF;Kao, HF;Su, YY;Shan, YS;Yen, CJ;Du, JS;Hsu, C;Wu, IC;Chen, LT |
| 國家衛生研究院 |
2024-03-25 |
Impact of previous S-1 treatment on efficacy of liposomal irinotecan plus 5-fluorouracil and leucovorin in patients with metastatic pancreatic cancer
|
Tang, CY;Yang, SH;Li, CP;Su, YY;Chiu, SC;Bai, LY;Shan, YS;Chen, LT;Chuang, SC;Chan, DC;Yen, CJ;Peng, CM;Chiu, TJ;Chen, YY;Chen, JS;Chiang, NJ;Chou, WC |
| 國家衛生研究院 |
2024-02-13 |
Germline mutations of homologous recombination genes and clinical outcomes in pancreatic cancer: A multicenter study in Taiwan
|
Cheng, SM;Su, YY;Chiang, NJ;Wang, CJ;Chao, YJ;Huang, CJ;Tsai, HJ;Chen, SH;Chang, CY;Tsai, CR;Li, YJ;Yen, CJ;Chuang, SC;Chang, JSM;Shan, YS;Hwang, DY;Chen, LT |
| 國家衛生研究院 |
2023-07-04 |
The impact of preoperative waiting time in Stage II-III gastric or gastroesophageal junction cancer: A population-based cohort study
|
Yen, CC;Yang, YH;Ku, HY;Hu, HM;Lo, SS;Chang, HC;Chao, Y;Chen, JS;Wang, HP;Wang, TE;Bai, LY;Wu, MS;Yen, CJ;Chen, LT;Shan, YS |
| 國家衛生研究院 |
2023-06-27 |
Comparison of therapeutic outcomes in esophageal squamous cell carcinoma following neoadjuvant chemoradiotherapy: A prospective observational cohort study
|
Liu, YW;Lee, JY;Wang, YK;Chen, YH;Fang, PT;Chou, SH;Chen, MH;Bai, LY;Yen, CJ;Wu, MT;Wu, IC |
| 國家衛生研究院 |
2023-02-05 |
Real-world data validation of NAPOLI-1 nomogram for the prediction of overall survival in metastatic pancreatic cancer
|
Su, YY;Chiang, NJ;Yang, YH;Yen, CJ;Bai, LY;Chiu, CF;Chuang, SC;Yang, SH;Chou, WC;Chen, JS;Chiu, TJ;Chen, YY;Chan, DC;Peng, CM;Chiu, SC;Li, CP;Shan, YS;Chen, LT |
| 國家衛生研究院 |
2023-02 |
ASO visual abstract: Distinct failure patterns in hypopharyngeal cancer patients receiving surgery-based versus radiation-based treatment
|
Lin, YH;Hsiao, JR;Wu, YH;Chang, JS;Ou, CY;Lee, WT;Huang, CC;Chang, CC;Lai, YH;Tsai, ST;Hsueh, WT;Yen, CJ;Lin, CL;Chen, YS;Jiang, SS;Su, YC;Wu, SY |
| 國家衛生研究院 |
2023-02 |
Distinct failure patterns in hypopharyngeal cancer patients receiving surgery-based versus radiation-based treatment
|
Lin, YH;Hsiao, JR;Wu, YH;Chang, JS;Ou, CY;Lee, WT;Huang, CC;Chang, CC;Lai, YH;Tsai, ST;Hsueh, WT;Yen, CJ;Lin, CL;Chen, YS;Jiang, SS;Su, YC;Wu, SY |
| 國家衛生研究院 |
2022-11-15 |
The impact of starting dose with or without subsequent dose escalation of liposomal irinotecan on treatment outcomes in patients with metastatic pancreatic ductal adenocarcinoma
|
Chiang, NJ;Shan, YS;Li, CP;Yang, SH;Su, YY;Chiu, SC;Bai, LY;Chuang, SC;Chan, DC;Yen, CJ;Peng, CM;Chiu, TJ;Chen, YY;Chen, JS;Chou, WC |
| 國家衛生研究院 |
2022-09-15 |
Predictive value of albumin combined with neutrophil-to-lymphocyte ratio for efficacy and safety profiles in patients with pancreatic ductal adenocarcinoma receiving liposomal irinotecan plus 5-fluorouracil and leucovorin
|
Chen, YY;Hsueh, SW;Yang, SH;Chiu, SC;Chiang, NJ;Chiu, TJ;Li, CP;Bai, LY;Chiu, CF;Chuang, SC;Shan, YS;Chan, DCA;Chen, LT;Yen, CJ;Peng, CM;Chen, JS;Chou, WC |
| 國家衛生研究院 |
2022-07 |
Improved survival with neoadjuvant chemotherapy in stage III pancreatic cancer: A single institutional experience
|
Ting, YL;Su, YY;Chiang, NJ;Chao, YJ;Li, YJ;Huang, CJ;Liao, TK;Su, PJ;Liu, IT;Tsai, HJ;Yen, CJ;Shan, YS;Chen, LT |
| 國家衛生研究院 |
2022-06-22 |
Dosing pattern and early cumulative dose of liposomal irinotecan in metastatic pancreatic cancer: A real-world multicenter study
|
Su, YY;Chiang, NJ;Li, CP;Yen, CJ;Yang, SH;Chou, WC;Chen, JS;Chiu, TJ;Chen, YY;Chuang, SC;Bai, LY;Chiu, CF;Peng, CM;Chan, DC;Chiu, SC;Yang, YH;Shan, YS;Chen, LT |
| 國家衛生研究院 |
2022-05-15 |
Improved survival with induction chemotherapy and conversion surgery in locally advanced unresectable pancreatic cancer: A single institution experience
|
Su, YY;Ting, YL;Wang, CJ;Chao, YJ;Liao, TK;Su, PJ;Chiang, NJ;Liao, IC;Yu, YT;Liu, YS;Tsai, HM;Li, YJ;Huang, CJ;Liu, IT;Tsai, HJ;Yen, CJ;Shan, YS;Chen, LT |
| 國家衛生研究院 |
2022-04-15 |
The impact of spleen volume on the survival of metastatic pancreatic adenocarcinoma patients receiving nanoliposomal irinotecan
|
Yang, SH;Chiang, NJ;Chiu, SC;Chou, WC;Bai, LY;Li, CP;Su, YY;Chiu, TJ;Chuang, SC;Peng, CM;Chan, DC;Chen, JS;Yen, CJ;Chen, YY;Chiu, CF;Chen, LT;Shan, YS |
| 國家衛生研究院 |
2022-02-19 |
Effect of previous conventional irinotecan treatment in patients with pancreatic cancer being treated with liposomal irinotecan plus 5-fluorouracil and leucovorin
|
Chiu, TJ;Yang, SH;Chiu, SC;Hsueh, SW;Chiang, NJ;Li, CP;Bai, LY;Cheng, FM;Chuang, SC;Shan, YS;Chan, DC;Chen, LT;Yen, CJ;Peng, CM;Su, YY;Chen, YY;Chen, JS;Chou, WC |
| 國家衛生研究院 |
2021-11-20 |
Liposomal irinotecan pre-emptive dose reduction in patients with pancreatic ductal adenocarcinoma: 667 patients’ experience within a population-based study
|
Chiu, TJ;Su, YY;Yang, SH;Li, CP;Bai, LY;Chiang, NJ;Chuang, SC;Shan, YS;Chan, DC;Chen, LT;Yen, CJ;Peng, CM;Chen, YY;Chen, JS;Chou, WC |
| 國家衛生研究院 |
2021-11-12 |
The prognostic and predictive role of chromogranin a in gastroenteropancreatic neuroendocrine tumors - A single-center experience
|
Tsai, HJ;Hsiao, CF;Chang, JS;Chen, LT;Chao, YJ;Yen, CJ;Shan, YS |
| 國家衛生研究院 |
2021-07-15 |
No association between alcohol consumption and pancreatic cancer even among individuals genetically susceptible to the carcinogenicity of alcohol
|
Shan, YS;Chen, LT;Wu, CH;Chang, YF;Lee, CT;Chiang, NJ;Chao, YJ;Yen, CJ;Tsai, HJ;Huang, HE;Tsai, CR;Weng, YL;Yang, HC;Liu, HC;Chang, JS |
| 國家衛生研究院 |
2021-06-12 |
Phase 1b study of pegylated arginine deiminase (ADI-PEG 20) plus Pembrolizumab in advanced solid cancers
|
Chang, KY;Chiang, NJ;Wu, SY;Yen, CJ;Chen, SH;Yeh, YM;Li, CF;Feng, XX;Wu, K;Johnston, A;Bomalaski, JS;Wu, BW;Gao, JJ;Subudhi, SK;Kaseb, AO;Blando, JM;Yadav, SS;Szlosarek, PW;Chen, LT |
| 國家衛生研究院 |
2021-05-04 |
Investigating the association between serum human papillomavirus type 16 E7 antibodies and risk of head and neck cancer
|
Huang, CC;Su, YC;Chang, CC;Lee, WT;Ou, CY;Wu, YH;Wu, SY;Lai, YH;Huang, JS;Chen, KC;Hsueh, WT;Tsai, ST;Yen, CJ;Chang, JY;Tsai, ML;Lin, CL;Weng, YL;Yang, HC;Chen, YS;Hsiao, JR;Chang, JS |
| 國家衛生研究院 |
2021-01-21 |
Metformin resensitizes sorafenib-resistant HCC cells through AMPK-dependent autophagy activation
|
Lai, HY;Tsai, HH;Yen, CJ;Hung, LY;Yang, CC;Ho, CH;Liang, HY;Chen, FW;Li, CF;Wang, JM |
| 國家衛生研究院 |
2021-01 |
Metformin resensitizes sorafenib-resistant HCC cells through AMPK-dependent autophagy activation
|
Lai, HY;Tsai, HH;Yen, CJ;Hung, LY;Yang, CC;Ho, CH;Liang, HY;Chen, FW;Li, CF;Wang, JM |
| 中山醫學大學 |
2021 |
Liposomal irinotecan pre-emptive dose reduction in patients with pancreatic ductal adenocarcinoma: 667 patients' experience within a population-based study
|
Chiu, TJ; Su, YY; Yang, SH; Li, CP; Bai, LY; Chiang, NJ; Chuang, SC; Shan, YS; Chan, DC; Chen, LT; Yen, CJ; Peng, CM; Chen, YY; Chen, JS; Chou, WC |
| 國家衛生研究院 |
2020-11-27 |
Phase I dose-escalation study of SCB01A, a microtubule inhibitor with vascular disrupting activity, in patients with advanced solid tumors
|
Shiah, HS;Chiang, NJ;Lin, CC;Yen, CJ;Tsai, HJ;Wu, SY;Su, WC;Chang, KY;Wang, CC;Chang, JY;Chen, LT |
| 國家衛生研究院 |
2020-11-13 |
The impact of liposomal irinotecan on the treatment of advanced pancreatic adenocarcinoma: Real-world experience in a Taiwanese cohort [Erraturm: Scientific Reports. 2020 May 4;10:Article number 7420.]
|
Su, YY;Chiang, NJ;Tsai, HJ;Yen, CJ;Shan, YS;Chen, LT |
顯示項目 1-25 / 99 (共4頁)
1 2 3 4 > >>
每頁顯示[10|25|50]項目
|
